Profile data is unavailable for this security.
About the company
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has five ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, one trial (CRDF-001) in second-line treatment in patients with mPDAC, and three investigator-initiated trials in first line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
- Revenue in USD (TTM)610.00k
- Net income in USD-40.25m
- Incorporated2009
- Employees31.00
- LocationCardiff Oncology Inc11055 Flintkote AveSAN DIEGO 92121-1220United StatesUSA
- Phone+1 (858) 952-7570
- Fax+1 (858) 217-4768
- Websitehttps://cardiffoncology.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sagimet Biosciences Inc | 2.00m | -27.88m | 147.45m | 10.00 | -- | 1.16 | -- | 73.72 | -1.31 | -1.31 | 0.0937 | 3.98 | -- | -- | -- | 200,000.00 | -- | -- | -- | -- | -- | -- | -1,393.80 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
| Context Therapeutics Inc | 0.00 | -21.32m | 150.00m | 5.00 | -- | 3.78 | -- | -- | -1.34 | -1.34 | 0.00 | 0.5288 | 0.00 | -- | -- | 0.00 | -99.14 | -- | -114.72 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
| Repare Therapeutics Inc | 97.86m | -45.69m | 150.68m | 179.00 | -- | 0.644 | -- | 1.54 | -1.10 | -1.10 | 2.30 | 5.51 | 0.3265 | -- | 9.22 | 546,698.30 | -15.25 | -23.40 | -18.73 | -26.37 | -- | -- | -46.69 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| X4 Pharmaceuticals Inc | 0.00 | -128.91m | 155.91m | 93.00 | -- | 150.50 | -- | -- | -0.6968 | -0.6968 | 0.00 | 0.0062 | 0.00 | -- | -- | 0.00 | -108.98 | -61.53 | -133.20 | -69.20 | -- | -- | -- | -13,288.93 | -- | -- | 0.9815 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
| Gossamer Bio Inc | 0.00 | -172.58m | 157.00m | 135.00 | -- | 5.88 | -- | -- | -1.05 | -1.05 | 0.00 | 0.1181 | 0.00 | -- | -- | 0.00 | -72.02 | -57.43 | -85.67 | -64.38 | -- | -- | -- | -- | -- | -14.73 | 0.8854 | -- | -- | -- | 21.61 | -- | -- | -- |
| ProQR Therapeutics NV | 14.66m | -29.18m | 157.83m | 157.00 | -- | 4.32 | -- | 10.76 | -0.3594 | -0.3594 | 0.1806 | 0.4493 | 0.0957 | -- | -- | 93,385.40 | -18.83 | -35.51 | -23.01 | -40.51 | -- | -- | -196.75 | -926.31 | -- | -- | 0.3557 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| Mediwound Ltd | 18.69m | -6.72m | 161.17m | 100.00 | -- | 4.96 | -- | 8.63 | -0.768 | -0.768 | 2.07 | 3.43 | 0.3209 | 6.28 | 2.87 | 186,860.00 | -11.53 | -24.48 | -14.35 | -32.92 | 19.15 | 43.27 | -35.94 | -38.43 | 4.33 | -- | 0.1674 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
| Cardiff Oncology Inc | 610.00k | -40.25m | 162.35m | 31.00 | -- | 2.67 | -- | 266.15 | -0.901 | -0.901 | 0.0137 | 1.36 | 0.0068 | -- | 1.14 | 19,677.42 | -44.55 | -31.24 | -50.10 | -33.56 | -- | -- | -6,594.92 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| Scilex Holding Co | 47.05m | -160.60m | 163.07m | 106.00 | -- | -- | -- | 3.47 | -1.28 | -1.28 | 0.3905 | -1.79 | 0.5307 | 5.53 | 1.92 | 448,047.60 | -121.78 | -- | -- | -- | 66.14 | -- | -229.47 | -- | 0.1356 | -12.49 | -- | -- | 22.90 | -- | -614.67 | -- | -- | -- |
| Rigel Pharmaceuticals Inc | 120.35m | -19.80m | 166.71m | 147.00 | -- | -- | -- | 1.39 | -0.1135 | -0.1135 | 0.69 | -0.1806 | 0.9623 | 0.9241 | 4.23 | 818,680.30 | -15.83 | -28.82 | -30.14 | -47.26 | 93.22 | 97.88 | -16.45 | -35.76 | 1.17 | -2.91 | 2.13 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| Adverum Biotechnologies Inc | 0.00 | -112.90m | 166.89m | 121.00 | -- | 0.9154 | -- | -- | -10.23 | -10.23 | 0.00 | 8.78 | 0.00 | -- | -- | 0.00 | -41.55 | -36.39 | -47.50 | -39.04 | -- | -- | -- | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| Alimera Sciences Inc | 80.75m | -21.39m | 167.60m | 159.00 | -- | 3.63 | -- | 2.08 | -2.16 | -2.16 | 3.17 | 0.8819 | 0.8235 | 6.22 | 2.98 | 507,886.80 | -20.53 | -19.08 | -29.94 | -27.37 | 86.58 | 86.80 | -24.93 | -19.55 | 2.31 | -0.1919 | 0.5835 | -- | 49.19 | 11.62 | -18.14 | -- | 236.53 | -- |
| Vaxart Inc | 8.89m | -81.74m | 169.55m | 109.00 | -- | 3.04 | -- | 19.08 | -0.5431 | -0.5431 | 0.059 | 0.3155 | 0.0813 | -- | 21.67 | 81,513.76 | -74.81 | -49.60 | -86.63 | -54.86 | -- | -- | -920.00 | -1,398.00 | -- | -- | 0.0705 | -- | 6,796.26 | 12.15 | 23.47 | -- | 21.49 | -- |
| Scpharmaceuticals Inc | 17.63m | -57.71m | 171.26m | 135.00 | -- | 6.97 | -- | 9.71 | -1.49 | -1.49 | 0.4545 | 0.6814 | 0.1713 | 0.7566 | 4.02 | 130,607.40 | -56.07 | -38.23 | -62.13 | -42.31 | 71.69 | -- | -327.29 | -1,360.16 | 5.44 | -16.60 | 0.6159 | -- | -- | -- | -48.79 | -- | -- | -- |
| Achieve Life Sciences Inc | 0.00 | -27.32m | 171.26m | 22.00 | -- | 3.46 | -- | -- | -1.29 | -1.29 | 0.00 | 1.44 | 0.00 | -- | -- | 0.00 | -60.15 | -86.31 | -109.37 | -119.59 | -- | -- | -- | -- | -- | -9.33 | 0.2574 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
| Kodiak Sciences Inc | 0.00 | -232.75m | 173.37m | 107.00 | -- | 0.7186 | -- | -- | -4.44 | -4.44 | 0.00 | 4.59 | 0.00 | -- | -- | 0.00 | -43.30 | -31.73 | -47.44 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
Data as of May 17 2024. Currency figures normalised to Cardiff Oncology Inc's reporting currency: US Dollar USD
14.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.91m | 4.27% |
| Laurion Capital Management LPas of 31 Mar 2024 | 928.72k | 2.08% |
| Millennium Management LLCas of 31 Mar 2024 | 683.30k | 1.53% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 670.88k | 1.50% |
| MAI Capital Management LLCas of 31 Mar 2024 | 551.12k | 1.23% |
| Geode Capital Management LLCas of 31 Mar 2024 | 434.83k | 0.97% |
| Marshall Wace LLPas of 31 Mar 2024 | 434.58k | 0.97% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 285.87k | 0.64% |
| Assenagon Asset Management SA (Germany)as of 31 Mar 2024 | 252.98k | 0.57% |
| William Blair Investment Management LLCas of 31 Mar 2024 | 172.18k | 0.39% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
